期刊文献+

不同阶段肝炎后肝硬化患者相关骨营养不良的研究 被引量:4

A research about different period cirrhosis after hepatitis patients who has osteoporosis disease
暂未订购
导出
摘要 目的探讨不同阶段肝炎后肝硬化患者当中骨营养不良的发病情况为相关并发症的防治提供理论依据。方法选择代偿性肝硬化(Child-Pugh A级)组55例,失偿性肝硬化(Child-Pugh B、C级)组35例,作为研究对象组,所选人群均为男性住院且排除肾脏疾病及内分泌系疾病。普通男性健康人群数量45名,所选人群均排除肝病、肾脏疾病及内分泌系疾病。检测Ca2+、血清甲状旁腺素(PTH)及降钙素(CT)、碱性磷酸酶同工酶(ALP3)、左侧桡骨下1/3处骨密度值,分别作对照。结果研究对象组随着病变的严重程度存在明显的血钙水平偏低,并且伴有血清甲状旁腺素升高而降钙素水平相对偏低,骨源性ALP3明显高于对照组,骨密度降低。结论不同阶段肝硬化患者普遍存在不同程度的骨吸收增加、骨形成下降的情况,主要表现为骨营养不良及骨质疏松症。 Objective The objective of this paper is to probe into osteoporosis disease incidence of cirrhosis after hepatitis patients,providing theory evidence to the prevention and cure of related complicating disease.Methods Select 90 male patients who are diagnosed as cirrhosis by hepatology professor of our hospital as random sample to research.all of whom are excluded the possibility of having kidney and endocrine disease.Simultaneously,randomly select 45 healthy males who coming to our hospital to do physical examination,and all of them are excluded the possibility of having hepatology,kidney and endocrine disease.Collect venous blood specimen from every patients from object group and control group to test Ca2 +,PTH,CT,ALP3 volume and the volume of left radius(at the 1、3 position) bone mineral density.Compare the volume of every patient from object group and control group.Results The comparison is that the level of blood calcium of patients from object group is obviously lower,furthermore the blood serum parathyroid hormone is higher and calcitonin is lower.The volume of ALP3 of patients diagnosed as cirrhosis is obviously higher than of patients from control group.Conclusion Cirrhosis patients in Jilin have increasing bone resorption and decreasing bone formation is a general condition.
出处 《中国实用医药》 2012年第30期25-26,共2页 China Practical Medicine
关键词 肝硬化 骨密度 骨质疏松症 Cirrhosis Bone mineral Density osteoporosis
  • 相关文献

参考文献6

  • 1Crawford BA,Kamc,Donaghy AJ,et al.The heterogeneity of bone disease in cirrosis:a multivariate analysis.Osteoporosis-Int,2003,14(2):987-994.
  • 2Sokhi RP,Anantharaju A,Kondaveeti R,et al.Bone mineral density among cirrhotic patients awaiting liver transplantation.Liver Transplant,2004,10(1):648-653.
  • 3赵锦程,李艳萍,陈立强.实验性肝硬化大鼠甲状旁腺素与降钙素的变化[J].黑龙江医药科学,2002,25(5):36-36. 被引量:3
  • 4保志军,马雄,邱德凯.慢性肝病并发骨质疏松的研究进展[J].中华消化杂志,2005,25(3):186-188. 被引量:7
  • 5Collier JD,Ninkovic M,Compston JE.Guidelines on the management of osteoporosis associated with chronic liver disease.Gut,2002,50(suppl 1):i1-i9.
  • 6郝连杰.肝脏与内分泌系统//王宝恩,张定凤主编.现代肝脏病学.北京:科学出版社,2003:165-168.

二级参考文献23

  • 1Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int, 1994,4: 368-381.
  • 2Collier JD, Ninkovic M, Compston JE. Guidelines on the management of osteoporosis associated with chronic liver disease. Gut, 2002,50(Suppl 1) :i1-i9.
  • 3Leslie WD, Bernstein CN, Leboff MS, et al. AGA technical review on osteoporosis in hepatic disorders. Gastroenterology,2003,125:941-966.
  • 4Newton J, Francis R, Prince M, et al. Osteoporosis in primary biliary cirrhosis revisited. Gut, 2001,49: 282-287.
  • 5Guichelaar MM, Malinchoc M, Sibonga J, et al. Bone metabolism in advanced cholestatic liver disease: analysis by bone histomorphometry. Hepatology, 2002,36: 895-903.
  • 6Duarte MP, Farias ML, Coelho HS, et al. Calcium-parathyroid hormone-vitamin D axis and metabolic bone disease in chronic viral liver disease. J Gastroenterol Hepatol, 2001, 16: 1022-1027.
  • 7Kong YY, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature, 1999,402: 304-309.
  • 8Aubin JE, Bonnelye E. Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. Osteoporos Int, 2000, 11: 905-913.
  • 9Gallego-Rojo FJ, Gonzalez-Calvin JL, Munoz-Torres M, et al.Bone mineral density, serum insulin-like growth factor-1, and bone turnover markers in viral cirrhosis. Hepatology, 1998,28:695-699.
  • 10Gonzalez-Calvin JL, Gallego-Rojo F, Fernandez-Perez R, et al.Osteoporosis, mineral metabolism, and serum soluble tumor necrosis factor receptor p55 in viral cirrhosis. J Clin Endocrinol metab, 2004,89: 4325-4330.

共引文献7

同被引文献34

引证文献4

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部